In 2021, two independent clinical studies demonstrated that FMT could promote the efficacy of anti-PD-1 therapy in 3/10 and 6/15 patients with PD-1-refractory melanoma, respectively (16, 17). The gene discussed is PDCD1; the disease is melanoma.